XERIS BIOPHARMA HOLDINGS INC (XERS)
Health Care · Rare disease biopharmaceuticals · NASDAQ
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug formulation platform for rare diseases.
What XERIS BIOPHARMA HOLDINGS INC does
Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. The company currently commercializes three FDA-approved products: Recorlev (for endogenous hypercortisolemia in Cushing's syndrome), Gvoke (ready-to-use liquid-stable glucagon for severe hypoglycemia), and Keveyis (for Primary Periodic Paralysis). Xeris also leverages its proprietary XeriSol and XeriJect non-aqueous formulation technologies to develop new therapies and pursue partnerships to enhance the drug delivery of other companies' compounds.
Themes: endocrine disorders, neurological diseases, diabetes care, drug delivery technology, orphan drugs, hypothyroidism treatment
Fundamentals
- Price$8.70 as of 2026-08-21 close
- Market cap$1.6B as of 2026-08-21
- 1-year return+14.6% 2025-08-21 close $7.59 → 2026-08-21 close $8.70
- P/E122.06 as of 2026-08-24
- Net margin+3.8% as of 2026-08-24
- Gross margin+85.9% as of 2026-08-24
- ROE+99.7% as of 2026-08-24
- Debt / equity17.00 as of 2026-08-24
- Revenue growth (YoY)+41.5% as of 2026-08-24
- Revenue CAGR (3y)+38.3% SEC XBRL
- Beta0.71 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How XERS compares in its sector
- price-to-earnings ratiotop 10% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How XERIS BIOPHARMA HOLDINGS INC looks technically
XERIS BIOPHARMA HOLDINGS INC (XERS) is trading 22.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 24 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive). It made a new 20-day high about 4 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 22.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +22.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.08 | $8.08 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.10 | $7.10 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 7.05. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 24 trading days ago — a "golden cross", a bullish long-term signal | 24 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($7.05 to $9.02) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 83.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.08 | $10.08 |
|---|---|---|
| From the 52-week high | it is 13.7% below its 52-week high (its highest price of the past year) | -13.7% |
| Above the 52-week low | it is 65.7% above its 52-week low (its lowest price of the past year) | +65.7% |
| Below the 52-week high | it is 13.7% below its highest point of the past year | 13.7% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $27.98 (set on 2018-09-12) | $27.98 |
| Given back of the 52-week move | over the past year its closes ranged ($5.29 to $9.90), and it has recovered well over two thirds of its fall from last year’s high — 74% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.14 to $8.29. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 74.0% |
| From the all-time high | it is 68.9% below its all-time high | -68.9% |
| Nearest price level | it is trading 3.1% above a support level at $8.43 — a price it turned at three times since 2025-09-19, most recently on 2026-01-08. Since 2024-08-21 it has 15 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.1% |
| All-time low | its lowest closing price on record is $0.9701 (set on 2023-01-05) | $0.9701 |
| Above the all-time low | it is 796.8% above its all-time low | +796.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 51st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3668 between its high and its low — about 4.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3668 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.65 and $8.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.65 – $8.32 – $8.98 |
| Typical daily range (% of price) | its price moves about 4.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.2% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges above its 200-day average price (22.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.94× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 7.1% above the previous close 49 sessions ago and has not traded back through the level it left behind at 6.24 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +7.0% |
| Gap filled | a 11.3% gap down opened on 2026-08-06 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 8 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.2 percentage points (the stock lost 0.9% while the market gained 2.3%) | -3.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 33.3 percentage points (the stock gained 36.4% while the market gained 3.1%) | +33.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 20.6 percentage points (the stock gained 31.6% while the market gained 11.1%) | +20.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 5.9 percentage points (the stock gained 14.6% while the market gained 20.5%) | -5.9% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.1% of the share price. | +8.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 24% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.02 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +24.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $8.30 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +4.9% |
Price levels it has turned at before
XERS last closed at $8.70 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.43 | Support | 3.1% below the last close | turned there three times · 2025-09-19 to 2026-01-08 |
| $9.01 | Resistance | 3.6% above the last close | turned there twice · 2026-07-07 to 2026-07-17 |
| $8.02 | Support | 7.9% below the last close | turned there twice · 2025-09-03 to 2026-07-14 |
| $7.82 | Support | 10.2% below the last close | turned there twice · 2025-10-13 to 2026-01-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $7.05.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-12, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · beating the market · At the top of its 14-day range (stochastic above 80) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.43 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$11.29 range $8.00 – $18.00; median $10.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for XERS
- Consensus EPS estimate-$0.02 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Recorlev faces competition from established medications and older generic drugs used off-label for Cushing's syndrome treatment, which could limit market penetration and revenue growth.","Clinical development of XP-8121 depends on successful Phase 3 trial initiation and completion in 2026, with delays or failures potentially impacting the company's pipeline value.","The company carries significant debt ($221.2 million in long-term debt as of March 31, 2026) relative to its modest profitability, creating financial leverage risk and limiting flexibility."]
What changed in the latest 10-Q
AI-assisted comparison of XERS's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- New disclosure in Item 1 (Legal Proceedings) filed 2026-05-07: Patent infringement lawsuits filed February 26, 2026 and March 20, 2026 by Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited against Torrent Pharmaceuticals Limited, Somerset Therapeutics LLC, Sandoz Inc., and Zydus Lifesciences Global FZZE regarding ANDA filings for generic version of Recorlev®.
- New disclosure filed 2026-05-07: Four Orange Book-listed patents for Recorlev® (U.S. Patent Nos. 11,020,393, 11,278,547, 11,903,940 and 12,377,096) scheduled to expire in March 2040.
- New disclosure filed 2026-05-07: Lawsuits seek injunction preventing FDA approval of ANDAs and permanent injunction preventing commercialization until patent expiration.
- New disclosure filed 2026-05-07: Automatic stay of FDA approval of ANDAs for up to 30 months triggered under Hatch-Waxman Act.
- New disclosure filed 2026-05-07: Financing activities reference to 'issuance of common shares in settlement of warrants of $8.2 million' for three months ended March 31, 2026.
- Removed:
- Removed from Item 1 (Legal Proceedings) filed 2026-05-07: Statement 'We are not currently subject to any material legal proceedings' that appeared in older filing.
- Removed from Item 1 filed 2026-05-07: General boilerplate language about legal proceedings in ordinary course and materiality assessment that appeared in 2025-11-06 filing.
- Reworded:
- Investing Activities period changed from 'nine months ended September 30, 2025' (2025-11-06) to 'three months ended March 31, 2026' (2026-05-07).
- Investing Activities reason changed from 'fewer purchases of short-term investments' (2025-11-06) to 'higher capital expenditures' (2026-05-07).
- Financing Activities period changed from 'nine months ended September 30, 2025' and 'nine months ended September 30, 2024' (2025-11-06) to 'three months ended March 31, 2026' and 'three months ended March 31, 2025' (2026-05-07).
- Financing Activities direction changed from 'net cash provided' (2025-11-06) to 'net cash used' (2026-05-07).
- Interest rate sensitivity amount changed from '$1.0 million' at September 30, 2025 (2025-11-06) to '$1.2 million' at March 31, 2026 (2026-05-07).
- Evaluation of Disclosure Controls and Procedures date changed from 'September 30, 2025' (2025-11-06) to 'March 31, 2026' (2026-05-07).
- SEC reference changed from 'U.S. Securities and Exchange Commission's ("SEC") rules and forms' (2025-11-06) to 'SEC rules and forms' (2026-05-07).
- Internal Control Changes date changed from 'three months ended September 30, 2025' (2025-11-06) to 'three months ended March 31, 2026' (2026-05-07).
- Critical Accounting Policies reference date changed from 'December 31, 2024' (2025-11-06) to 'December 31, 2025' (2026-05-07).
- NEW ACCOUNTING STANDARDS note reference changed from 'Note 2 - Basis of presentation...' (2025-11-06) to 'Note 2 — Basis of presentation...' (2026-05-07) (dash style change).
- Notes:
- The two filings cover different periods: the newer filing is for Q1 2026 (three months ended March 31, 2026) while the older filing is for nine months ended September 30, 2025, making period-to-period comparisons inherently different.
- The legal proceedings disclosure represents a material substantive change from 'no material legal proceedings' to active patent litigation, but this reflects actual new lawsuits filed in February-March 2026 and is not a restatement of prior periods.
- Financing activities figures differ in both direction (provided vs. used) and magnitude due to different reporting periods and different activities in each period.
Risk Factors
- Added:
- Newer filing (2026-05-07) shows cash and cash equivalents of $111,750 thousand as of March 31, 2026, compared to $111,042 thousand as of December 31, 2025
- Newer filing shows trade accounts receivable of $56,295 thousand as of March 31, 2026, compared to $51,050 thousand as of December 31, 2025
- Newer filing shows inventory of $74,234 thousand as of March 31, 2026, compared to $68,673 thousand as of December 31, 2025
- Newer filing shows accounts payable of $11,467 thousand as of March 31, 2026, compared to $3,076 thousand as of December 31, 2025
- Newer filing shows long-term debt of $221,224 thousand as of March 31, 2026, compared to $220,335 thousand as of December 31, 2025
- Newer filing shows net income of $2,234 thousand for three months ended March 31, 2026, compared to net loss of $9,220 thousand for three months ended March 31, 2025
- Newer filing shows product revenue of $82,454 thousand for three months ended March 31, 2026, compared to $57,802 thousand for three months ended March 31, 2025
- Newer filing shows 172,558,783 common shares outstanding as of March 31, 2026, compared to 166,215,410 shares as of December 31, 2025
- Newer filing includes issuance of 2,275,313 common shares in settlement of warrants for the three months ended March 31, 2026
- Newer filing shows operating cash flow of $9,870 thousand for three months ended March 31, 2026, compared to negative $10,031 thousand for three months ended March 31, 2025
- Removed:
- Older filing (2025-11-06) included current portion of long-term debt of $15,102 thousand as of December 31, 2024, not shown in newer filing structure
- Older filing showed debt refinancing costs of negative $2,690 thousand in nine months ended September 30, 2024, not reflected in newer filing period
- Older filing included change in fair value of warrants and contingent value rights line items in operations statement for 2024 comparisons, not present in newer filing
- Reworded:
- Newer filing references page numbers as 29-31 for Items 1A-6 in table of contents, older filing references pages 32-34
- Balance sheet comparison dates differ: newer filing compares March 31, 2026 to December 31, 2025; older filing compared September 30, 2025 to December 31, 2024
- Statements of operations comparison periods differ: newer filing shows three months ended March 31, 2026 vs 2025; older filing showed three months and nine months ended September 30, 2025 vs 2024
- Stockholders' equity section header changed from 'Stockholders' equity (deficit)' in older filing to 'Stockholders' Equity' in newer filing
- Notes:
- These are different quarters being reported (Q1 2026 vs Q3 2025), so period-to-period comparisons reflect different fiscal periods and business activities rather than purely accounting changes
- The documents appear to be truncated; older filing stockholders' equity table is incomplete at bottom, limiting full comparison of that section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 12 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 3 sells ($296293) — 3 selling insiders
- Last 90 days0 buys · 12 sells ($2M) — 7 selling insiders
- Last 180 days0 buys · 14 sells ($2M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-12. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about XERS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding XERS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 19,317,129
- Reported value $112,039,349
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
XERS had 9,221,405 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
XERS had 5.06% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.75 days to cover at the same settlement.
- Reported short interest (shares) 9,221,405
- Short interest (% of shares outstanding) 5.06%
- Prior settlement (shares) 10,078,469
- Reported change -8.5%
- Days to cover (reported) 6.75
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Novo Nordisk (NVO)
- Strongbridge Biopharma (acquired by Xeris)
- Amryt Pharma (acquired by Chiesi)
- Crinetics Pharmaceuticals (CRNX)
- BridgeBio Pharma (BBIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare XERS vs…
XERIS BIOPHARMA HOLDINGS INC is found in…
XERS ranks in…
Frequently asked questions
What does XERIS BIOPHARMA HOLDINGS INC (XERS) do?
Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. The company currently commercializes three FDA-approved products: Recorlev (for endogenous hypercortisolemia in Cushing's syndrome), Gvoke (ready-to-use liquid-stable glucagon for severe hypoglycemia), and Keveyis (for Primary Periodic Paralysis).
What sector is XERIS BIOPHARMA HOLDINGS INC (XERS) in?
XERIS BIOPHARMA HOLDINGS INC (XERS) is classified in the Health Care sector. Its industry is Rare disease biopharmaceuticals. It trades on NASDAQ.
Who are XERIS BIOPHARMA HOLDINGS INC's (XERS) competitors?
Notable peers of XERIS BIOPHARMA HOLDINGS INC (XERS) include Eli Lilly, Novo Nordisk, Strongbridge Biopharma (acquired by Xeris), Amryt Pharma (acquired by Chiesi) and Crinetics Pharmaceuticals. This peer set is informational only — not financial advice.
Is XERIS BIOPHARMA HOLDINGS INC (XERS) overbought or oversold right now?
XERIS BIOPHARMA HOLDINGS INC (XERS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on XERS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.